安进Amgen Inc. (AMGN) 2015年年度报告「NASDAQ」.pdf

1、Dear Shareholders,2015 was a momentous year for Amgen.It was a year in which we delivered impressive financial results and an unprecedented six innovative new product offerings to the market,each of which helped serve patients suffering from serious illness.In doing so,we demonstrated clear progress

2、 toward our 2018 commitments to investors and solidly advanced our strategy for long-term growth.We achieved record results in revenues and earnings in 2015.The strengths of our products were reflected in eight percent revenue growth,to a record$21.7 billion.Our 19 percent adjusted earnings per shar

3、e*growth reflects tight control of our business and the benefits of our ongoing transformation effortsefforts that were launched company-wide three years ago.Beyond delivering record operating results for 2015,we made substantial progress along every dimension of our strategy:advancing innovative me

4、dicines and a portfolio of biosimilar medicines to address serious illness;expanding our geographic reach;transitioning to next-generation manufacturing;improving our biologic drug delivery systems;and allocating capital to shareholders while investing substantially in our business for long-term gro

5、wth.My intent in this letter is to briefly address the progress we have made on each of these strategic elements.A Clear,Long-Term Strategy for Growth and Value CreationFounded 35 years ago,Amgens mission is clear:it is to serve patients.Our strategy is also clear:it is to develop innovative medicin

6、es that meet important unmet medical needs.This focus guided us when we developed our first medicine three decades ago for patients suffering from kidney disease.The same unwavering focus inspired us as we launched six innovative products during the past year,including our novel medicine for certain